Monitoring Disease Progression and Deciding When to Initiate Next Line Therapy

Program Description

This Phone-a-Friend™ activity module features 2 MM experts discussing how to monitor disease progression and assess risk, and factors to consider when deciding to initiate next line therapy in a patient with RRMM. 

Target Audience

This activity is intended for hematologic oncology clinicians, including physicians, fellows, nurse practitioners (NPs), nurses, and physician associates (PAs), in both the academic and the community setting.

Educational Objectives

Upon completion of this activity, participants should be able to:

• Identify patients with RRMM, evaluating past response to treatment, MRD, and functional status, to inform future management decisions 

Disclosures of Relevant Financial Relationships

Integritas Communications and Global Education Group adhere to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Caitlin Costello, MD: Consultant: Bristol Myers Squibb, Genentech, Janssen Pharmaceuticals, Karyopharm, Pfizer Inc., and Regeneron

Joseph Mikhael, MD, MEd, FRCPC, FACP: Consultant: Amgen, Bristol Myers Squibb, Janssen Pharmaceuticals, and Sanofi

The planners and managers at Integritas Communications and Global Education Group have no relevant financial relationships to disclose.

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 0.25 contact hours, including 0.0 pharmacotherapeutic contact hours, is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For information about the accreditation (ACCME credit) of this program, please contact Integritas at info@exchangecme.com.

Global Contact Information

For information about the accreditation (ANCC) of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.